1464 related articles for article (PubMed ID: 19801028)
1. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
[TBL] [Abstract][Full Text] [Related]
3. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Frere C; Cuisset T; Quilici J; Camoin L; Carvajal J; Morange PE; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Thromb Haemost; 2007 Oct; 98(4):838-43. PubMed ID: 17938809
[TBL] [Abstract][Full Text] [Related]
4. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
Cotton JM; Worrall AM; Hobson AR; Smallwood A; Amoah V; Dunmore S; Nevill AM; Raghuraman RP; Vickers J; Curzen N
Cardiovasc Ther; 2010 Jun; 28(3):139-46. PubMed ID: 20406238
[TBL] [Abstract][Full Text] [Related]
5. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Cuisset T; Frere C; Quilici J; Morange PE; Camoin L; Bali L; Lambert M; Juhan-Vague I; Alessi MC; Bonnet JL
Thromb Res; 2009 Feb; 123(4):597-603. PubMed ID: 18499233
[TBL] [Abstract][Full Text] [Related]
6. High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Mielot C; Bali L; Lambert M; Alessi MC; Bonnet JL
Thromb Haemost; 2007 Feb; 97(2):282-7. PubMed ID: 17264958
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
[TBL] [Abstract][Full Text] [Related]
8. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
[TBL] [Abstract][Full Text] [Related]
10. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
11. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
Frere C; Cuisset T; Morange PE; Quilici J; Camoin-Jau L; Saut N; Faille D; Lambert M; Juhan-Vague I; Bonnet JL; Alessi MC
Am J Cardiol; 2008 Apr; 101(8):1088-93. PubMed ID: 18394438
[TBL] [Abstract][Full Text] [Related]
12. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818
[TBL] [Abstract][Full Text] [Related]
13. Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Cuisset T; Hamilos M; Delrue M; Frère C; Verhamme K; Bartunek J; Saut N; Bonnet JL; Eijgelsheim M; Wijns W; Alessi MC; Barbato E
Thromb Haemost; 2010 Apr; 103(4):774-9. PubMed ID: 20135061
[TBL] [Abstract][Full Text] [Related]
14. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.
Cuisset T; Frere C; Quilici J; Morange PE; Nait-Saidi L; Carvajal J; Lehmann A; Lambert M; Bonnet JL; Alessi MC
J Am Coll Cardiol; 2006 Oct; 48(7):1339-45. PubMed ID: 17010792
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up.
Marcucci R; Gori AM; Paniccia R; Giusti B; Valente S; Giglioli C; Buonamici P; Antoniucci D; Abbate R; Gensini GF
Circulation; 2009 Jan; 119(2):237-42. PubMed ID: 19118249
[TBL] [Abstract][Full Text] [Related]
16. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
18. Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Cuisset T; Quilici J; Grosdidier C; Fourcade L; Gaborit B; Pankert M; Molines L; Morange PE; Bonnet JL; Alessi MC
Am J Cardiol; 2011 Nov; 108(10):1411-6. PubMed ID: 21872198
[TBL] [Abstract][Full Text] [Related]
19. Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention.
Motovska Z; Odvodyova D; Fischerova M; Stepankova S; Maly M; Morawska P; Widimsky P
Am J Cardiol; 2012 Mar; 109(5):620-3. PubMed ID: 22154314
[TBL] [Abstract][Full Text] [Related]
20. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
Blindt R; Stellbrink K; de Taeye A; Müller R; Kiefer P; Yagmur E; Weber C; Kelm M; Hoffmann R
Thromb Haemost; 2007 Dec; 98(6):1329-34. PubMed ID: 18064332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
